GEMP Gemphire Therapeutics Inc.

0  0%
Previous Close 11.65
Open 11.56
Price To book 5.23
Market Cap 107.83M
Shares 9,272,000
Volume 41,884
Short Ratio 1.22
Av. Daily Volume 27,400

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to be initiated in 2H 2017.
Gemcabene - AZURE-1
Nonalcoholic steatohepatitis (NASH) / Nonalcoholic fatty liver disease (NAFLD)
Phase 2b data due 4Q 2017.
Gemcabene - INDIGO-1
Severe Hypertriglyceridemia (SHTG)
Phase 2b data due 3Q 2017.
Gemcabene - ROYAL-1
Heterozygous Familial Hypercholesterolemia (HeFH)
Phase 2b data due June 2017. Interim data released January 30, 2017.
Gemcabene - COBALT-1
Homozygous Familial Hypercholesterolemia (HoFH)

Latest News

  1. Gemphire Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
  2. Gemphire Therapeutics (GEMP) is in Overbought Territory: What's Next?
  3. Gemphire Therapeutics (GEMP) Catches Eye: Stock Gains 12%
  4. Gemphire Therapeutics Announces Presentation at ACC Meeting of Phase 2 Clinical Trial Investigating Effect of Gemcabene on Insulin Sensitization
  5. Gemphire to Present at the Oppenheimer Annual Healthcare Conference and the H.C. Wainwright NASH Investor Event
  6. Gemphire Announces Fiscal Year 2016 Financial Results and Provides Corporate Update
  7. Gemphire Therapeutics to Report Fiscal Year End 2016 Financial Results on Wednesday, March 15
  8. Gemphire Therapeutics Announces $12.5 Million Financing
  9. Amgen's LDL-Buster Boosts The Medicines Co., But Regeneron Slides
  10. Gemphire Therapeutics to Participate in the Canaccord Genuity Rare Disease and Biopharma 1 on 1 Day and the RBC Capital Markets Global Healthcare Conference
  11. Gemphire Announces Interim LDL-C Lowering Data from COBALT-1 Phase 2b Clinical Trial
  12. LifeSci Capital Initiates Coverage of Gemphire Therapeutics
  13. How Xenon Pharmaceuticals Inc (XENE) Stacks Up Against Its Peers
  14. Three Appealing Micro-Cap Stocks
  15. 4 Analyst Upgrades Moving Stocks Higher
  16. Gemphire Therapeutics' Oral Cholesterol Drug Could Have $2.8 Billion Potential In U.S. Market
  17. Gemphire Therapeutics Inc. (GEMP): Cormorant Asset Management Reports New Stake